Evidence Table H1. Articles/arms for class ANTI-BACTERIAL (ORAL).

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
H.01.01	**56**	**Clindamycin**	150 mg oral bid.	*Qid 1 week, tid 1 week, then bid. Chosen by patient and included: antibacterial soaps, antibacterial cleanser, various peeling agents. Encouraged not to start/stop ancillary treatment after initiation of study.*	**Vehicle**	No dose information	*Qid 1 week, tid 1 week, then bid. Chosen by patient and included: antibacterial soaps, antibacterial cleanser, various peeling agents. Encouraged not to start/stop ancillary treatment after initiation of study.*	Continuous Discrete
H.01.02	**265**	**Clindamycin**	150 mg oral (qid 1 week; tid second week then bid)	*Pernox® nightly; Transact bid.*	**Tetracycline**	250 mg oral (qid one week; tid week 2 then bid)	*Pernox® nightly; Transact bid.*	Continuous Discrete
	275	**Clindamycin hydrochloride**	150 mg oral qd.	*Non-antibacterial soap and shampoo.*	**Tetracycline hydrochloride**	250 mg oral bid.	*Non-antibacterial soap and shampoo.*	Discrete
H.02.01	**71**	**Demethylchlortetracycline**	150 mg oral qid.		**Vehicle**	No dose information		Discrete
	162	**Demethylchlortetracycline**	150 mg oral qid.	*Well-known soap and bedtime lotion.*	**Placebo**	No dose information		Discrete
	192	**Demethylchlortetracycline**	150 mg oral qd.	*Supply taken until exhausted. Common acne cleansers and drying lotions.*	**Placebo**	No dose information	*Supply taken until exhausted (24 capsules). Common acne cleansers and drying lotions.*	Discrete
	193	**Demethylchlortetracycline**	150 mg oral qhs.	*24 tabs provided and told to complete.*	**Placebo**	No dose information		Discrete
	312	**Demethylchlortetracycline**	150 mg oral qid.	*After meals.*	**Placebo**	No dose information	*1/2 hour after meals.*	Continuous Discrete
H.02.02	**312**	**Demethylchlortetracycline**	150 mg oral qid.	*After meals.*	**Phenethicillin**	250 mg oral qid.	*1/2 hr. Before meals.*	Continuous Discrete
H.02.03	**70**	**Demethylchlortetracycline**	150 mg oral tid.	*Qid until response, then reduced to tid, bid, qd, as tolerated, and until a total of 300 capsules used.*	**Tetracycline**	250 mg oral tid.		Discrete
	71	**Demethylchlort**	150 mg oral qid.		**Tetracycline**	250 mg oral qid.		Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING Treatment	Dose, route, frequency	*Comments, ancillary treatment*	COMPARATOR Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Outcome Table(s)
		etracycline			**hydrochloride**			
H.03.01	**273**	**Doxycycline**	200 mg oral qd.	*2 capsules in A.M.*	**Placebo**	No dose information	*2 capsules in A.M.*	Continuous Discrete
H.03.02	**1**	**Doxycycline**	50 mg oral qd.		**Fusidin**	2 % topical qhs.		Continuous Discrete
H.03.03	**25**	**Placebo** **Doxycycline**	No dose information. 100 mg oral (qod)	*For 2 weeks bid; then one cap 90d. Tioxolon® powder 0.1%.*	**Placebo** **Erythromycin stearate**	No dose information 250 mg oral bid.	*500 mg bid x 2 weeks; then 250 mg bid x 4 weeks. Tioxolon® powder 0.1%.*	Continuous
H.03.04	**155**	**Doxycyline**	50 mg oral qd.	*Chlorhexidine 4% + benzoyl peroxide 5%..*	**Minocycline**	50 mg oral bid.	*Chlorhexidine 4% + benzyol peroxide 5%..*	Continuous Discrete
	257	**Placebo** **Doxycycline**	No dose information. 50 mg oral bid.	*Reduced to qd after 4 weeks.*	**Placebo** **Minocycline**	No dose information 50 mg oral bid.	*Reduced to qd after 4 weeks.*	Continuous Discrete
	311	**Doxycycline**	100 mg oral qhs.	*5% salicylic acid & 5% resorcinolin spir dit. Ket. Preparation applied twice a day.*	**Minocycline**	100 mg oral qhs.	*5% salicylic acid & 5% resorcinolin spir dit. Ket. Preparation applied twice a day.*	Continuous Discrete
H.04.02	**24**	**Erythromycin**	500 mg oral bid.	*Local treatment with Tioxolon® (camyra powder 0.1%, bid).*	**Erythromycin**	500 mg oral bid.	*Local treatment with Tioxolon® (camyra powder 0.1 %, bid).*	Continuous Discrete
H.04.03	**6**	**Erythromycin**	250 mg oral bid.		**Tetracycline**	250 mg oral bid.		Discrete
	36	**Erythromycin acistrate**	200 mg oral qd.	*Week 1: 400 mg bid; week 2: 200 mg bid; following weeks: 200 mg qd.*	**Tetracycline**	250 mg oral qd.	*Week 1: 500 mg bid; week 2: 250 mg bid; following weeks: 250 mg qd.*	Continuous Discrete
	125	**Placebo** **Erythromycin**	No dose information. 500 mg oral qd.	*Erythromycin tid for first 4 weeks; placebo bid for first 4 weeks. Gently wash affected area twice daily with Purpose®.*	**Placebo** **Placebo** **Tetracycline**	No dose information No dose information No dose information	*Tetracycline bid for first 4 weeks; placebo tid for first 4 weeks. Gently wash affected area twice daily with Purpose® ®soap.*	Continuous Discrete
H.04.04	**340**	**Erythromycin proprionate**	No dose information.		**Triacetyl-oleandomycin**	No dose information		Discrete (M)
		Erythromycin	No dose information.	*Dosage described as "3*	**Triacetyl-**	No dose information		Discrete (M)

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
		stearate		*doses daily for at least 60 days and after that they (pts) could adjust the dose as they felt they needed to do.". Acne surgery done by the author; resorciline sulfur preparation once daily, usually at bedtime.*	**oleandomycin**			
H.04.05	**4**	**Roxithromycin**	150 mg oral qd.		**Roxithromycin**	300 mg oral qd.		Discrete
H.04.06	**247**	**Oleandomycin**	250 mg oral qid.		**Triacetyl-oleandomycin**	250 mg oral qid.		Discrete
H.05.01	**161**	**Minocycline**	100 mg oral qd.	*200 mg qd x1 week, then 100 mg qd x 4 weeks.*	**Placebo**	No dose information	*Identical in appearance to minocycline.*	Continuous Discrete
H.05.02	**268**	**Minocycline**	50 mg oral qd.	*Simple soap twice daily.*	**Clindamycin**	1 % topical bid.	*Simple soap twice daily.*	Continuous Discrete
	307	**Placebo**	No dose information.	*Before meals.*	**Placebo**	No dose information	*Applied to entire face.*	Continuous
		Minocycline	50 mg oral bid.		**Clindamycin phosphate**	1 % topical bid.		
H.05.04	**72**	**Minocycline**	50 mg oral bid.		**Tetracycline**	250 mg oral bid.		Continuous Discrete
	171	**Minocycline**	50 mg oral bid.		**Tetracycline hydrochloride**	250 mg oral bid.		
	298	**Minocycline**	50 mg oral bid.		**Tetracycline**	250 mp oral bid.		Continuous Discrete
H.06.01	**250**	**Oxytetracycline**	125 mg oral qd.	*Before meal; cross to placebo at 1 to 3 months. Standard program = hands off, soap and water 3x day, apply prescribed resocrinol and sulfur shake lotion at night, keep hair clean, take sun baths.*	**Placebo**	No dose information	*Before meal; cross to oxytetracycline at 1 to 3 months. Standard program = hands off, soap and water 3x day, apply prescribed resocrinol and sulfur shake lotion at night, keep hair clean, take sun baths.*	Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
H.06.02	**255**	**Oxytetracycline**	250 mg oral bid.		**Placebo**	No dose information		Continuous Discrete
		Vehicle	No dose information.		**Benzoyl peroxide**	5 % topical qd.		
H.06.03	**123**	**Vehicle**	No dose information.	*Tablets taken 30minutes before meals.*	**Placebo**	No dose information		Discrete
		Oxytetracycline	250 mg oral bid.		**Metronidazole**	2 % topical bid.		
					Benzoyl peroxide	5 % topical bid.		
H.06.04	**40**	**Tetracycline**	2.2 % topical bid.	*1.25mg/day n-decyl methyl sulphoxide. Oral tetracycline 1000mg/day 1st 4 weeks, 500 day next 4 weeks, out of 16 weeks total study duration.*	**Placebo**	70 ml topical bid.	*Oral tetracycline-1000 mg/day 1st 4 weeks, 500 mg/day next 4 weeks out of 16 weeks total study duration.*	Continuous Discrete
H.06.05	**255**	**Oxytetracycline**	250 mg oral bid.		**Placebo**	No dose information		Continuous Discrete
		Vehicle	No dose information.		**Tetracycline**	No dose information		
H.06.06	**152**	**Oxytetracycline**	250 mg oral bid.		**Sulphamethoxazole**	400 mg oral bid.		Continuous Discrete
					Trimethoprim	80 mg oral bid.		
H.06.07	**128**	**Oxytetracycline**	250 mg oral tid.	*Tid for 4 weeks then bid.*	**Trimethoprim**	100 mg oral tid.	*Tid for 4 weeks then bid.*	Continuous Discrete
H.07.01	**160**	**Sulphamethoxazole**	400 mg oral qd.		**Vehicle**	No dose information		Continuous
		Trimethoprim	80 mg oral qd.					
	223	**Cotrimoxazole**	No dose information.	*Strength of tablet not mentioned. Washing with soap.*	**Placebo**	No dose information	*Washing with soap.*	Continuous Discrete
H.07.02	**41**	**Sulfadimethoxine**	500 mg oral bid.	*1 g bid for 1 week; 0.5 g qd for 4 weeks. Cleaning soap and water; exposure to Westinghouse® sun lamp acne lotion.*	**Placebo**	No dose information		Discrete
H.08.01	**10**	**Tetracycline**	250 mg oral bid.		**Placebo**	250 mg oral bid.		Continuous Discrete
		Vehicle	No dose information.		**Vehicle**	No dose information		

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
H.08.01	**23**	**Tetracycline hydrochloride** **Placebo**	250 mg oral bid. No dose information.		**Placebo** **Placebo**	No dose information No dose information	*Non-antibacterial soap and shampoo.*	Continuous
	33	**Vehicle** **Tetracycline**	No dose information. 250 mg oral bid.		**Vehicle** **Vehicle**	No dose information No dose information		Continuous Discrete
	69	**Tetracycline**	250 mg oral bid.	*Qid x 2 wks, then tid x 4 wks, then bid.*	**Topical treatment**	No dose information	*Local treatment was one or combination of lotion, ointment or pastes and cryotherapy. Active ingredients were not mentioned.*	Discrete
	71	**Tetracycline hydrochloride**	250 mg oral qid.		**Vehicle**	No dose information		Discrete
	136	**Placebo** **Tetracycline hydrochloride**	No dose information. 250 mg oral bid.	*Placebo for clindamycin. Vehicle isopropyl alcohol+water.*	**Placebo solution** **Placebo capules**	No dose information No dose information	*Placebo solution vehicle isopropyl alcohol water. Placebo for tetracycline and for clindamycin.*	Continuous Discrete
	201	**Tetracycline**	250 mg oral bid.		**Placebo**	No dose information		Continuous Discrete
	313	**Placebo** **Tetracycline hydrochloride**	No dose information. 250 mg oral bid.	*Non-antibacterial soaps and shampoo.*	**Placebo** **Placebo**	No dose information No dose information	*Non-antibacterial soaps and shampoo.*	Continuous
H.08.02	**29**	**Vehicle** **Tetracycline**	No dose information. 250 mg oral bid.	*Capsule taken on empty stomach every morning & evening, one hour before or 2 hours after meals.*	**Placebo** **Clindamycin phosphate**	No dose information 1 % topical bid.	*Dabbed on skin every morning and night after washing.*	Continuous
	33	**Vehicle** **Tetracycline**	No dose information. 250 mg oral bid.		**Vehicle** **Clindamycin**	No dose information No dose information	*Clindamycin pH adjusted.*	Continuous Discrete
	136	**Placebo** **Tetracycline hydrochloride**	No dose information. 250 mg oral bid.	*Placebo for clindamycin. Vehicle isopropyl alcohol+water.*	**Placebo** **Clindamycin phosphate**	No dose information 1 % topical bid.	*Placebo for tetracycline. Vehicle isopropyl alcohol+water.*	Continuous Discrete
	186	**Tetracycline hydrochloride**	500 mg oral bid.	*Placebo (topical) for 1st 3 weeks, 2x1day. For remainder of 9 weeks: 250mg (2 x day) + placebo (topical) (2x day).*	**Placebo** **Clindamycin**	No dose information 1 % topical bid.	*4 pts. Missed more than 1 follow-up visit; 5 had too many lesions; and, 7 had too few papules.*	Continuous Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING Treatment	Dose, route, frequency	*Comments, ancillary treatment*	COMPARATOR Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Outcome Table(s)
H.08.02	**318**	**Placebo** **Tetracycline**	No dose information. 250 mg oral bid.	*Placebo for Clindamycin phosphate.*	**Clindamycin phosphate**	No dose information	*Placebo for tetracycline.*	
H.08.03	**279**	**Placebo** **Tetracycline hydrochloride**	No dose information. 250 mg oral bid.		**Placebo** **Erythromycin**	No dose information 1.5 % topical bid.		Continuous Discrete
H.08.04	**10**	**Tetracycline** **Vehicle**	250 mg oral bid. No dose information.		**Placebo** **Tetracycline**	250 mg oral bid. 0.5 % topical bid.		Continuous Discrete
	23	**Tetracycline hydrochloride** **Placebo**	250 mg oral bid. No dose information.		**Placebo** **Tetracycline hydrochloride**	No dose information 0.5 % topical (can't say)	*Non-antibacterial soap and shampoo.*	Continuous
	313	**Placebo** **Tetracycline hydrochloride**	No dose information. 250 mg oral bid.	*Non-antibacterial soaps and shampoo.*	**Placebo** **Tetracycline hydrochloride**	No dose information 0.5 % topical bid.	*0.5% tetracycline = 0.22% tetracycline hcl + 0.28% 4-epi-tracycline HCl. Non-antibacterial soaps and shampoo.*	Continuous
H.08.05	**22**	**Tetracycline**	250 mg oral qid.		**Azelaic acid**	20 % topical bid.		Continuous Discrete
	166	**Tetracycline hydrochloride**	500 mg oral (can't say)	*1000 mg/day for first month, 750 mg/day for second.*	**Placebo** **Placebo** **Azelaic acid**	No dose information No dose information 20 % topical bid.		Continuous Discrete
	167	**Placebo** **Tetracycline hydrochloride**	No dose information. 500 mg oral ()	*1000 mg /day for first month, 750 mg/day for the second month, 500 mg/day for third month, then adjusted as needed.*	**Placebo** **Azelaic acid**	No dose information 20 % topical bid.		Continuous Discrete
H.08.06	**164**	**Tetracycline** **Vehicle**	250 mg oral bid. No dose information.	*The placebo cream is the vehicle base of meclosorb®.*	**Placebo** **Meclocycline sulfosalicylate**	No dose information 1 % topical bid.		Continuous
H.08.08	**212**	**Tetracycline**	250 mg oral qd.	*1st month bid; 2nd qd; 3rd every other day. Usual cosmetics and soap.*	**Tetracycline hydrochloride**	250 mg oral bid.	*1st month bid; 2nd qd; 3rd every other day. Usual cosmetics and soap.*	Discrete
	317	**Proteolytic enzymes**	50000 units oral qid.	*Enzymes: chymotropin/tryposin 1:6.*	**Tetracycline**	250 mg oral qid.		Discrete

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
		Tetracycline	250 mg oral qid.					
		Tetracycline	250 mg oral qid.		**Proteolytic enzymes** **Tetracycline**	50000 units oral qid. 250 mg oral qid.	*Enzymes: chymotropin/tryposin 1:6.*	Discrete
H.08.085	**299**	**Sodium novobiocin** **Tetracycline**	125 mg oral qid. 250 mg oral qid.	*Tried for 2 weeks with 4 capsules a day then increase or decrease but ideal was 4/d. Non abrasive soap; 1% salicyclic acid in ethyl alcohol; sulfur-resorcin lotion.*	**Placebo**	No dose information	*Non abrasive soap; 1% salicyclic acid in ethyl alcohol; sulfur-resorcin lotion.*	
H.08.14	**236**	**Tetracycline** **Povidone-iodine**	250 mg oral bid. No dose information.	*Povidone-iodine is bid to tid.*	**Vehicle** **Tetracycline**	No dose information 250 mg oral bid.		Discrete
H.09.01	**293**	**Dapsone**	No dose information.		**Placebo**	No dose information		Discrete
H.09.02	**312**	**Phenethicillin**	250 mg oral qid.	*1/2 hr. Before meals.*	**Placebo**	No dose information	*1/2 hour after meals.*	Continuous Discrete
H.09.04	**344**	**Fusidin**	250 mg oral qd.		**Fusidin**	2 % topical bid.		Discrete
H.09.05	**340**	**Tetracycline-novobiocin**	No dose information.		**Placebo**	No dose information		Discrete (M)

"(M)" indicates that data are found on the Multi-Arm tables.